NewTimeSpace News:As of 09:50 on February 27, 2026, the CSI Medical Index (399989) rose 0.65%. Its constituent stocks posted strong gains: Huitai Medical surged 10.62%, Intco Medical climbed 5.06%, Weining Health advanced 2.68%, Haoyuan Pharmaceutical rose 2.03% and Tongce Medical increased 1.85%. The Hwabao WP CSI Medical Service ETF (512170) rose 0.57% to the latest price of RMB 0.35. (The stocks listed above are only constituent stocks of the index and do not constitute any investment recommendation.)

In terms of liquidity, the Hwabao WP CSI Medical Service ETF recorded an intraday turnover rate of 0.57% with a trading volume of RMB 159 million. As of February 26, its average daily trading volume in the past month stood at RMB 634 million, ranking first among comparable funds.

In terms of scale, the ETF has achieved a notable growth of RMB 223 million in size over the past two weeks, ranking in the top quarter among comparable funds in terms of new scale added. (Data source: Wind)

In terms of outstanding shares, the latest share count of the Hwabao WP CSI Medical Service ETF reached 78.8 billion, a new high in the past six months, ranking in the top quarter among comparable funds. (Data source: Wind)

In terms of capital inflows, the ETF saw a net capital inflow of RMB 116 million recently. Over the past four trading days, it has attracted a total of RMB 178 million in capital. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The net margin purchase volume of the Hwabao WP CSI Medical Service ETF on the previous trading day reached RMB 69.9505 million, with the latest margin balance standing at RMB 1.089 billion. (Data source: Wind)

As of February 26, the net asset value of the Hwabao WP CSI Medical Service ETF has risen 0.40% in the past year. In terms of profitability, as of February 26, 2026, since its inception, the ETF has achieved a maximum monthly return of 29.81%, a longest consecutive monthly gain streak of 6 months with a cumulative increase of 26.58% during the streak, and an average return of 6.80% in months with gains. As of February 26, 2026, the ETF has delivered an annualized excess return of 1.72% over the benchmark since its establishment.

In terms of drawdown, as of February 26, 2026, the Hwabao WP CSI Medical Service ETF's relative benchmark drawdown year-to-date was 0.12%.

In terms of fees, the Hwabao WP CSI Medical Service ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of February 26, 2026, the ETF's tracking error over the past five years was 0.038%, the highest tracking accuracy among comparable funds.

Notably, the CSI Medical Index tracked by the fund is at a historically low valuation level, with the latest price-to-book ratio (PB) standing at 3.58 times, lower than that in more than 83.84% of the period since the index's inception, representing prominent valuation cost performance.

The Hwabao WP CSI Medical Service ETF closely tracks the CSI Medical Index, which selects securities of listed companies in the medical and health industry engaged in medical device, medical service, medical informatization and other medical-themed businesses as its sample stocks, so as to reflect the overall performance of securities of medical-themed listed companies.

Data showed that as of January 30, 2026, the top 10 weight stocks of the CSI Medical Index (399989) were WuXi AppTec, Mindray Medical, United Imaging Healthcare, Aier Eye Hospital Group, Tigermed, Pharmaron, Yuyue Medical, Lepu Medical, Meinian Onehealth and New Industries Biomedical Engineering. The combined weight of the top 10 stocks accounted for 50.64% of the index. (The stocks listed above are only constituent stocks of the index and do not constitute any investment recommendation.)

AVIC Securities stated that AI-driven drug discovery is accelerating, and domestic medical large models have demonstrated international competitiveness. Medical companies at home and abroad have been continuously deploying AI products and services, including medical imaging, clinical decision support, precision medicine, health management, medical informatization, drug research and development, and medical robots. AI is evolving from a role of "technical assistance" to a core driving force for the "value reshaping" and "efficiency revolution" of the medical industry, and its commercial value is fully penetrating from the R&D end to the clinical, payment and patient ends.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.